JP2019527239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527239A5 JP2019527239A5 JP2019519608A JP2019519608A JP2019527239A5 JP 2019527239 A5 JP2019527239 A5 JP 2019527239A5 JP 2019519608 A JP2019519608 A JP 2019519608A JP 2019519608 A JP2019519608 A JP 2019519608A JP 2019527239 A5 JP2019527239 A5 JP 2019527239A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- acute
- independently
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126560 MAPK inhibitor Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000013078 crystal Substances 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 102000043136 MAP kinase family Human genes 0.000 claims 6
- 108091054455 MAP kinase family Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000003032 molecular docking Methods 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000010505 Nose Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 claims 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000002612 dispersion medium Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000001167 myeloblast Anatomy 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 208000037830 nasal cancer Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 208000024724 pineal body neoplasm Diseases 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000008759 sweat gland cancer Diseases 0.000 claims 1
- 201000008753 synovium neoplasm Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022006150A JP7372993B2 (ja) | 2016-06-23 | 2022-01-19 | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353856P | 2016-06-23 | 2016-06-23 | |
| US62/353,856 | 2016-06-23 | ||
| US201762469913P | 2017-03-10 | 2017-03-10 | |
| US62/469,913 | 2017-03-10 | ||
| PCT/US2017/038697 WO2017223284A1 (en) | 2016-06-23 | 2017-06-22 | NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006150A Division JP7372993B2 (ja) | 2016-06-23 | 2022-01-19 | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527239A JP2019527239A (ja) | 2019-09-26 |
| JP2019527239A5 true JP2019527239A5 (enExample) | 2020-07-30 |
| JP7013453B2 JP7013453B2 (ja) | 2022-01-31 |
Family
ID=60784745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519608A Active JP7013453B2 (ja) | 2016-06-23 | 2017-06-22 | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
| JP2022006150A Active JP7372993B2 (ja) | 2016-06-23 | 2022-01-19 | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006150A Active JP7372993B2 (ja) | 2016-06-23 | 2022-01-19 | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US20190151324A1 (enExample) |
| EP (1) | EP3474835B1 (enExample) |
| JP (2) | JP7013453B2 (enExample) |
| CN (2) | CN109640970B (enExample) |
| AU (4) | AU2017281222B2 (enExample) |
| WO (1) | WO2017223284A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3474835B1 (en) * | 2016-06-23 | 2023-07-05 | University of Maryland, Baltimore | Non-catalytic substrate-selective p38 -specific mapk inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
| CA3122371A1 (en) * | 2018-12-07 | 2020-06-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| US11286260B2 (en) * | 2020-05-18 | 2022-03-29 | Gen1E Lifesciences Inc. | P38α mitogen-activated protein kinase inhibitors |
| AU2021370893B2 (en) * | 2020-10-29 | 2024-03-07 | Gen1E Lifesciences Inc. | Crystalline 5-(dimethylamino) -n- (4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate |
| IL306101A (en) | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
| CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
| WO2023004438A2 (en) * | 2021-07-22 | 2023-01-26 | The General Hospital Corporation | Fret-based assays |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR96352E (fr) | 1967-12-29 | 1972-06-16 | Science Union & Cie | Nouveaux dérives du spiro (4,5) decane et leur procédé de préparation. |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| DE19801646A1 (de) | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte alpha,beta-annellierte Butyrolactone |
| JPH11269146A (ja) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
| RU2380369C9 (ru) | 2002-09-04 | 2011-07-10 | Шеринг Корпорейшн | Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| CA2514791A1 (en) | 2003-02-13 | 2004-08-26 | Aventis Pharma Deutschland Gmbh | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments |
| US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| WO2005100338A1 (en) | 2004-04-13 | 2005-10-27 | Astex Therapeutics Limited | 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators |
| EP1868616A2 (en) * | 2005-03-29 | 2007-12-26 | The University of Maryland, Baltimore | Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor |
| TW200904421A (en) * | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
| JP5555186B2 (ja) | 2008-02-29 | 2014-07-23 | クロマ セラピューティクス リミテッド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| EP2355826A1 (en) | 2008-11-07 | 2011-08-17 | The Cleveland Clinic Foundation | Compounds and methods of promoting oligodendrocyte precursor differentiation |
| WO2010082912A1 (en) * | 2009-01-15 | 2010-07-22 | Avalon Pharmaceuticals | Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents |
| UY32462A (es) * | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| RU2015125595A (ru) | 2013-01-15 | 2017-02-21 | Карл Алекс МЮЛЛЕР | Быстрая твердофазная реакция оксидов с использованием ультрафиолетового излучения |
| EP3004087B1 (en) * | 2013-06-06 | 2017-08-09 | CHIESI FARMACEUTICI S.p.A. | Derivatives of [1,2,4]triazolo[4,3-a]pyridine as p38-map kinase inhibitors |
| US9025712B2 (en) | 2013-07-30 | 2015-05-05 | Pixart Imaging Inc. | Sensor, clock frequency adjusting system and method thereof |
| EP3105222B1 (en) * | 2014-02-14 | 2018-04-11 | Respivert Limited | Aromatic heterocyclic compounds as antiinflammatory compounds |
| GB201417168D0 (en) * | 2014-09-29 | 2014-11-12 | Univ Hertfordshire Higher Education Corp | Compounds |
| US10865181B2 (en) * | 2014-11-05 | 2020-12-15 | University Of Kansas | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) |
| EP3474835B1 (en) * | 2016-06-23 | 2023-07-05 | University of Maryland, Baltimore | Non-catalytic substrate-selective p38 -specific mapk inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
| TW201829381A (zh) | 2016-12-22 | 2018-08-16 | 美商拜奧馬林製藥公司 | 組蛋白脫乙醯基酶抑制劑 |
| CA3122371A1 (en) | 2018-12-07 | 2020-06-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| WO2021183970A1 (en) | 2020-03-13 | 2021-09-16 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| US11286260B2 (en) | 2020-05-18 | 2022-03-29 | Gen1E Lifesciences Inc. | P38α mitogen-activated protein kinase inhibitors |
-
2017
- 2017-06-22 EP EP17816192.3A patent/EP3474835B1/en active Active
- 2017-06-22 US US16/312,499 patent/US20190151324A1/en not_active Abandoned
- 2017-06-22 WO PCT/US2017/038697 patent/WO2017223284A1/en not_active Ceased
- 2017-06-22 JP JP2019519608A patent/JP7013453B2/ja active Active
- 2017-06-22 AU AU2017281222A patent/AU2017281222B2/en active Active
- 2017-06-22 CN CN201780051906.8A patent/CN109640970B/zh active Active
- 2017-06-22 CN CN202310509095.9A patent/CN116570594A/zh active Pending
-
2021
- 2021-04-15 US US17/231,598 patent/US11357781B2/en active Active
-
2022
- 2022-01-19 JP JP2022006150A patent/JP7372993B2/ja active Active
- 2022-05-09 US US17/740,248 patent/US11911392B2/en active Active
- 2022-08-19 AU AU2022218616A patent/AU2022218616B2/en active Active
-
2023
- 2023-02-15 US US18/169,785 patent/US11911393B2/en active Active
-
2024
- 2024-01-18 US US18/416,532 patent/US20240366619A1/en active Pending
- 2024-05-01 AU AU2024202879A patent/AU2024202879B2/en active Active
-
2025
- 2025-10-31 AU AU2025259977A patent/AU2025259977A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527239A5 (enExample) | ||
| AU2015335391B2 (en) | Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer | |
| RU2468016C2 (ru) | СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl СО СВЯЗЫВАЮЩИМИ ПАРТНЕРАМИ | |
| JP2013507415A5 (enExample) | ||
| JP2010510214A5 (enExample) | ||
| JP2008521928A5 (enExample) | ||
| JP2016536283A5 (enExample) | ||
| AU2017200232A1 (en) | Combination therapy | |
| JP2017510641A5 (enExample) | ||
| TWI726362B (zh) | Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用 | |
| JP2020515571A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| PH12020500327A1 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| JP2015509540A5 (enExample) | ||
| HRP20192101T1 (hr) | Inhibitori ezh2 | |
| JP2016513704A5 (enExample) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| EP3716978B1 (en) | N-(phenyl)-n'-(6-quinoxalinyl)-urea derivatives as ikkb inhibitors for the treatment of cancer | |
| RU2016147654A (ru) | Соединения для лечения рака | |
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| CN109689652A (zh) | 稠杂环类衍生物、其制备方法及其在医学上的应用 | |
| WO2013170758A1 (zh) | 含稠环结构的苯甲酰胺类化合物及其作为抗肿瘤药物应用 | |
| JP7018514B2 (ja) | 化合物及びその薬学での応用 | |
| JP2013528215A5 (enExample) | ||
| RU2014128387A (ru) | Ингибиторы рi3к для лечения фиброзных заболеваний |